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796Objective: Moxifloxacin reduces infectious complications after cerebral damage, such as ischemia and stroke.
This study investigated whether moxifloxacin treatment influences cerebral inflammation and improves cognitive
outcome after cardiopulmonary bypass with deep hypothermic circulatory arrest in rats.
Methods:Rats were randomly assigned to deep hypothermic circulatory arrest (n¼ 40), sham operation (n¼ 40),
and untreated control (n ¼ 20) groups. Deep hypothermic circulatory arrest and sham groups were equally sub-
divided into moxifloxacin and placebo subgroups, receiving 63 100mg/kg moxifloxacin or saline solution every
2 hours intraperitoneally. Hippocampal tumor necrosis factor a, nuclear factor kB, cyclooxygenase 2, and mac-
rophages were assessed immunohistochemically. Histologic outcome was determined with hematoxylin and eo-
sin. Neurologic outcome was assessed preoperatively and postoperatively. Cognitive performance was tested
with the modified hole board test for 14 postoperative days.
Results: On postoperative day 14, deep hypothermic circulatory arrest moxifloxacin group was lower than deep
hypothermic circulatory arrest placebo group in hippocampal neurons positive for tumor necrosis factor a (1.33,
0.73–2.37, vs 4.10, 2.42–18.67), nuclear factor kB (3.03, 1.33–5.20, vs 9.32, 2.53–24.14), and cyclooxygenase 2
(3.16, 0.68–6.04, vs 8.07, 3.27–19.91) and also had fewer macrophages than all other groups (72, 60–90, vs deep
hypothermic circulatory arrest placebo 128, 76–203, sham moxifloxacin 89, 48–96, and sham placebo 81,
47–87). On postoperative day 14, both deep hypothermic circulatory arrest groups showed impaired motor,
cognitive, and histologic outcomes relative to sham-operated groups, with no difference between deep hypother-
mic circulatory arrest subgroups.
Conclusions:Moxifloxacin transiently reduces cerebral inflammatory reaction, but without impact on neurologic
function, histologic outcome, or long-term cognitive performance. (J Thorac Cardiovasc Surg 2011;141:796-802)Anti-inflammatory substances such as the fluoroquinolone
moxifloxacin (a Bayer product), a synthetic broad-spectrum
antibiotic, can reduce infectious complications after such
forms of cerebral damage as ischemia and stroke. This effect
has been demonstrated after middle cerebral artery occlusion
in mice, with moxifloxacin reducing poststroke infection
and ameliorating neurologic outcome.1 This effect has
been attributed mainly to the anti-infective activity of the
substance, with infection presenting a severe consequence
of stroke.2 In addition to its well-known anti-infective
characteristics, moxifloxacin provides immunomodulatory
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The Journal of Thoracic and Cardiovascular Surgimmunomodulation is considered equally important for
reducing inflammation and improving survival in vitro and
in vivo.3,4 The significance of immunomodulation alone on
functional outcome, without infection, is not yet known.
The rat model of cardiopulmonary bypass (CPB) with
deep hypothermic circulatory arrest (DHCA) allows investi-
gation of cerebral inflammation without clinical and bio-
chemical signs of infection.5 The initiated inflammatory
cascade includes the activation of tumor necrosis factor
a (TNFa),6 as well as nuclear transcription factor kB
(NFkB).7 This study was designed to investigate whether
moxifloxacin treatment primarily influences the cerebral in-
flammatory reaction on a biochemical or histologic level and
to determine whether moxifloxacin treatment secondarily
improves cognitive or motor function after CPB with
DHCA in rats.
MATERIALS AND METHODS
Animals and Study Design
After institutional animal care committee approval, 100 male Sprague–
Dawley rats (330–400 g; Charles River, Sulzfeld, Germany) were housed
under standard laboratory conditions (12 hours light/12 hours dark, 22C,
60% humidity, and free access to water and standard laboratory rat diet)
for 3 weeks before the experiments for acclimatization.ery c March 2011
Abbreviations and Acronyms
COX-2 ¼ cyclooxygenase 2
CPB ¼ cardiopulmonary bypass
DHCA ¼ deep hypothermic circulatory arrest
NFkB ¼ nuclear transcription factor kB
TNFa ¼ tumor necrosis factor a
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SA total of 100 rats were randomly assigned to DHCA (n¼ 40), sham op-
eration (n ¼ 40), and control (n¼ 20) groups. These groups were then sub-
divided, with half of each respective group (DHCA n ¼ 20, sham n ¼ 20,
control n ¼ 10) allowed to survive for 24 hours. The remaining half of
each group (DHCA n ¼ 20, sham n ¼ 20, control n ¼ 10) was allowed
to survive for 14 days. The DHCA and sham-operated groups were further
split equally into moxifloxacin (n ¼ 10) and placebo (n ¼ 10) groups, re-
ceiving either moxifloxacin (63 100mg/kg intraperitoneally every 2 hours,
beginning with the onset of anesthesia) or a placebo (saline solution and
1 mol/L hydrochloric acid, adjusted to pH 7 with sodium hydroxide). The
DHCA group rats were anesthetized, cannulated, connected to CPB, and
subjected to 45 minutes of DHCA. The sham group rats were anesthetized
and surgically cannulated but not connected to CPB, whereas rats in the con-
trol group remained untreated. Short-term cerebral inflammatory response
and neurologic and histologic outcomes were studied in animals killed after
24 hours; long-term motor and cognitive function were studied in animals
killed on the 14th postoperative day. Long-term histologic outcome on post-
operative day 14 was also determined.
CPB and DHCA
Rats were intubated and mechanically ventilated with oxygen in air at an
inspired oxygen fraction of 40% (arterial PCO2, 32—40 mmHg). All instru-
ments were disinfected, catheters were gas sterilized, and surgery was car-
ried out in an aseptic manner. Surgical sites were infiltrated with 2%
lidocaine (Xylocaine). During surgical preparation, anesthesia was main-
tained with 2% to 2.5% isoflurane and 5-mg fentanyl bolus doses. Heparin
(150 IU) was administered. The tail artery (aortic inflow), the right superfi-
cial epigastric artery (blood pressure monitoring), and the right external jug-
ular vein (venous drainage) were cannulated as previously described.5
Pericranial and rectal temperatures were monitored.
CPBwas set up as previously described.5 The setup consisted of a venous
reservoir, a peristaltic pump, a membrane oxygenator with integrated water
quench, and an arterial inflow cannula, all connected by 1.6-mm internal di-
ameter plastic tubing. An in-line flow probe (2N806 flow probe and T208
volume flowmeter; Transonics Systems, Inc, Ithaca, NY) was used to con-
tinuously measure CPB flow. CPBwas instituted at a flow rate of 160 to 180
mL/(min $ kg) and was consecutively decreased by half during the cooling
period. With rectal temperature reaching 15C to 18C after 30 minutes, the
roller pump was turned off and venous blood was drained to the reservoir.
Circulatory arrest, as confirmed by asystole and lack of measurable mean
arterial pressure, was maintained for 45 min at 15C to 18C. With the re-
institution of CPB, rewarming started at a rectal temperature of 15C to
18C and a flow rate of 105 mL/(min $ kg). This inflow rate was gradually
increased, reaching the full rate of 160 to 180mL/(min $ kg) at the end of the
rewarming phase. Once a rectal temperature of at least 35.5C was reached,
CPB was terminated.
During CPB, anesthesia consisted of 0.8% to 1% isoflurane, cisatracu-
rium besylate (INN cisatracurium besilate, 1.6 mg/h), and fentanyl bolus
doses (5 mg). A continuous positive airway pressure mode (5 cm H2O, in-
spired oxygen fraction 0.21) was applied to avoid atelectasis. During
DHCA, anesthesia was discontinued. During rewarming, mean arterial pres-
sure was kept above 50 mm Hg by norepinephrine as soon as a rectalThe Journal of Thoracic and Catemperature of 30C and a blood flow of 150 mL/(min $ kg) were achieved.
Arterial blood gas values were controlled with the pH-stat strategy (arterial
PCO2 of 31 to 40 mm Hg).
After cessation of CPB, rats remained anesthetized with 1.0% to 1.5%
isoflurane, intubated, and ventilated for 1 hour (rectal temperature 36.5C).
Bicarbonate was administered to treat acidosis, and calcium was injected to
prevent a drop of ionized calcium below 1mmol/L. The heparin-induced an-
ticoagulation was allowed to dissipate spontaneously. When animals re-
sumed spontaneous breathing, the tracheas were extubated and the rats
were placed under continuous observation for 12 hours in a transparent,
oxygen-enriched box with free access to water and food. Animals were re-
turned to their cages at the first postoperative day and were housed in their
familiar groups. According to group assignment, rats were killed either at 24
hours or 14 days after CPB with DHCA. Animals were anesthetized, serum
samples were harvested, and brains were removed and snap frozen on dry
ice and stored at80C for further analyses.
Assessment of Biochemical Outcomes
The concentrationsofmoxifloxacinweredetermined in serumsampleshar-
vested 24 hours after DHCA and in brain tissue homogenates with a reverse-
phase high-performance liquid chromatographicmethodwith fluorimetric de-
tection at an excitation frequency of 396 nmand an emission frequency of 504
nm.8 The limits of quantification (signal to noise ratio 10/1) for serum brain
tissue moxifloxacin were 20 ng/mL and 20 ng/g, respectively.
Serum samples of all groups taken 24 hours after DHCA were analyzed
for TNFa levels by enzyme-linked immunosorbent assay with a minimum
detectable level of 5 pg/mL (Qantikine; R&D Systems, Wiesbaden-
Nordenstadt, Germany).
To detect hippocampal neurons positive for TNFa (polyclonal rabbit
anti-TNFa; Acris Antibodies, Hiddenhausen, Germany), NFkB (polyclonal
rabbit anti-NFkB p65; Abcam, Cambridge, UK), and cyclooxygenase 2
(COX-2; monoclonal rabbit anti–COX-2, Cell Signaling; Beverley,
Mass), an immunohistochemical double staining was performed (7 mm;
3.3 mm caudal from bregma [bregma -3.3 mm]) for each inflammatory
marker. Neurons were labeled with an anti–neuronal nuclei antibody
(Mouse Anti–Neuronal Nuclei Monoclonal Antibody; Millipore, Billerica,
Mass). Neurons positive for TNFa, NFkB, and COX-2 were counted
throughout the hippocampus under a light microscope (3400).
Macrophages of rats killed at 24 postoperative hours were marked
(CD68 mouse anti–human macrophage marker; United States Biological
Inc, Swampscott, Mass) on brain slices (7 mm; bregma -3.3 mm) and
counted throughout the hippocampus (3400).
Assessment of Histologic Outcome
Cell damage in the hippocampus was assessed in brain slices (7 mm;
bregma -3.3mm) stained with hematoxylin and eosin (according to the num-
ber of eosinophilic neurons throughout the hippocampus (3400) of the rats
killed at 24 postoperative hours. To represent the complexity of ischemic
damage 14 days after DHCA, a modified score was used.9 The number of in-
tact neurons was graded on an incremental 3-point scale (0 representing
100% intact neurons, 1 representing 99%–95% intact neurons, 2 represent-
ing 94%–84% intact neurons, and 3 representing83% intact neurons). In
addition, numbers of cerebral infarcts were assessed and scored on an incre-
mental 3-point scale (for size: 0 representing no infarction, 1 representing 1
to 5mm2, 2 representing 6 to 10mm2, and 3 representingmore than 10mm2;
for number: 0 representing no infarcts, 1 representing 1 infarct, 2 represent-
ing 2 infarcts, and 3 representing more than 2 infarcts). Score values were
summed to provide a total histologic score for each animal, with the score
varying between 0 (normal brain) and 12 (maximal damage).Assessment of Functional Outcomes
To assess short-term motor function, animals underwent standardized
functional neurologic testing both on the preoperative day and on the dayrdiovascular Surgery c Volume 141, Number 3 797
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FIGURE 1. Inflammatory parameters nuclear factor kB (NFkappaB),
cyclooxygenase 2 (COX-2), and tumor necrosis factor a (TNFalpha) in hip-
pocampus 1 day after deep hypothermic circulatory arrest (DHCA).A, Deep
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Sthey were killed. Motor function was scored from performances on a beam
and a rotating grid, time hanging on a rope, movement symmetry, and gait.5
Consequently, each animal tested received score values from 0 through 18,
with 0 to 1 representing normal motor function.
For the assessment of long-term outcome, animals were allowed to sur-
vive for 14 postoperative days. At the end of the experiment, motor function
was assessed as described previously, complemented by 2 fine motor skill
parameters from the modified hole board test (time per food intake, number
of abortive hole visits). Cognitive and behavioral function were assessed
with daily testing in the modified hole board test according to an established
protocol.10 Briefly, the rats lived in an area divided into home cage
(80 3 603 50 cm) and test arena (40 3 60 3 50 cm), with the hole board
(20 3 40 cm) placed in the middle of the test arena. Fifteen cylinders were
staggered on the board and baitedwith almonds underneath a grid. Three cyl-
inders that were marked with white tape contained almonds above the grid
and, therefore, obtainable for the rats. All cylinders were treated with black
currant aroma to cover smell of the almonds.
On the second and third postoperative days, animals were habituated to
the hole board and the almonds. Beginning with the fourth postoperative
day, rats learned the test until postoperative day 14. Animals were tested
in the modified hole board test for 3 trials daily. The sequence of marked
cylinders was randomly changed every day.
Motor and cognitive function were scored as previously described,5 with
every animal receiving score values from 0 to 24 for motor and cognitive
performance and 0 to 22 for behavior, with 0 to 1 representing normal
motor, cognitive, and behavioral function.
Statistics and Data Management
Data are presented as box and whisker plots. Biochemical, histologic,
and functional outcomes were analyzed with the Kruskal–Wallis test with
post hoc Mann–Whitney U. Motor function and cognitive performance
were assessed with a previously described scoring system.5 Individual func-
tional parameters were recorded as score values (maximum scores being the
worst outcome) and summed to total motor scores (0–18 and 0–24, respec-
tively) and a total cognition score (0–24) for each animal at the end of the
experiment. Statistical analyzes were performed with SPSS version 16.0 for
Windows (SPSS Inc, an IBM Company, Chicago, Ill).RESULTS
Nine animals were excluded from further data analysis be-
cause of cannulation problems (n¼ 3) or insufficient venoushypothermic circulatory arrest placebo group shows highest numbers of hip-
pocampal neurons positive for nuclear factor kB relative to all other groups.
Data are presented as box and whisker plot. Asterisk indicates P<.001 ver-
sus deep hypothermic circulatory arrest placebo; section mark indicates
P< .001 versus sham moxifloxacin; crosshatch indicates P< .001 versus
sham placebo. Dashed line marks 90th percentile of untreated controls. B,
Placebo group shows highest numbers of hippocampal neurons positive
for cyclooxygenase 2 relative to sham groups and untreated controls.
Data are presented as box and whisker plot. Asterisk indicates P¼ .007 ver-
sus deep hypothermic circulatory arrest placebo; section mark indicates
P< .001 versus sham moxifloxacin; crosshatch indicates P< .001 versus
sham placebo. Dashed lines mark 10th and 90th percentiles of untreated
controls. C, Deep hypothermic circulatory arrest placebo group shows high-
est numbers of hippocampal neurons positive for tumor necrosis factor a rel-
ative to all other groups. Data are presented as box and whisker plot.
Asterisk indicates P< .001 versus deep hypothermic circulatory arrest pla-
cebo; section mark indicates P< .001 versus sham moxifloxacin; cross-
hatch indicates P< .001 versus sham placebo. Dashed line marks 90th
percentile of untreated controls.
:
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FIGURE 2. Macrophages in hippocampus 1 day after deep hypothermic
circulatory arrest (DHCA).Number of macrophages in hippocampus was el-
evated in deep hypothermic circulatory arrest placebo group relative to all
other groups. Data are presented as box and whisker plot. Asterisk indicates
P ¼ .001 versus all other groups. Dashed line marks 90th percentile of
untreated controls.
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equal.
Moxifloxacin was detectable in brain and serum at 24
postoperative hours, with significantly higher levels in the
DHCA group than in the sham group (brain DHCA group,
1.52  0.24 and sham group, 0.28  0.07 mg/g; serum
DHCA group, 5.71  0.93 and sham group, 1.25  0.03).
Serum TNFa levels at 24 hours after DHCA, assessed
with enzyme-linked immunosorbent assay, were below the
limit of quantification of 5 pg/mL (DHCA groups, 1.16 
0.26 pg/mL; sham groups, 0.98  0.22 pg/mL). In the early
postoperative phase, hippocampal TNFa, NFkB, and COX-
2-expressions were significantly higher in the DHCA
placebo group than in the DHCA moxifloxacin group. The
higher expressions of inflammatory parameters in the
DHCA placebo group were accompanied by elevated num-
bers of macrophages in the hippocampus relative to all other
groups (Figures 1 and 2).
At both 24 hours and 14 days after CPB with DHCA, his-
tologic outcomes were impaired in both DHCA groups rela-
tive to the sham groups. There was no effect of moxifloxacin
treatment (Figure 3).
At 24 postoperative hours, motor function was impaired
in both DHCA groups relative to sham groups, with no effect
of moxifloxacin treatment (Figure 4). At 14 postoperative
days, both motor and cognitive functions were impaired in
both DHCA groups relative to sham groups, with no effect
of moxifloxacin treatment. Behavioral parameters were
comparable among all experimental groups (Figure 5).
DISCUSSION
Moxifloxacin transiently reduced inflammation in the
brain 24 hours after CPB with DHCA in rats, but without
any influence on short-term histologic and neurologic out-
comes. This early anti-inflammatory effect of moxifloxacin
did not alter motor and cognitive performance 14 days after
CPB with DHCA.
The recovery model of DHCA in rats induces both motor
and neurocognitive deficits, dependent on the duration of
DHCA. In this study, 45 minutes of DHCA was chosen to
induce a minor cerebral insult with a high survival rate but
sufficiently detectable effects on both neurologic and neuro-
cognitive performances.5 As intended, rats showed postop-
erative impairments in cognitive function and motor
deficits after DHCA relative to sham-operated rats. The his-
tologic examination correspondingly revealed neuronal cell
damage. Even more important for studying the impact of an
anti-inflammatory drug,11 however, is that this model of
DHCA induced a severe inflammatory reaction in placebo-
treated rats, as evidenced by higher numbers of macro-
phages and upregulation of neuronal TNFa, NFkB, and
COX-2 levels.
We found clinically relevant amounts of moxifloxacin12
in both the brain and the serum 24 hours after DHCA,The Journal of Thoracic and Cawhereas the sham-operated moxifloxacin-treated rats
showed only minor concentrations. In both groups, though,
moxifloxacin was equally distributed between serum and
brain tissue. The 4-fold higher moxifloxacin concentration
in the DHCA group 20 hours after last administration of
the drug was most likely due to slower metabolism and
reduced tissue perfusion in this group, leading to the prolon-
gation of the substance’s half-life.
Cerebral moxifloxacin significantly reduced the number
of macrophages in this early postoperative phase and
simultaneously curbed neuronal expressions of TNFa,
NFkB, and COX-2 in the hippocampus at 24 postoperative
hours. The effect on macrophages and their secretory
products13 is of particular interest, because fluoroquino-
lones are suspected to inhibit the activation of early cell
signaling events associated with the inflammatory re-
sponse,14 with moxifloxacin for example directly inhibit-
ing the interleukin 1b–induced nuclear translocation of
NFkB.4
The previously mentioned early anti-inflammatory effect
of moxifloxacin in the hippocampus, however, had no ben-
efit in terms of histologic damage. At both 24 hours and
14 days after DHCA, histologic outcome was unaffected
by the moxifloxacin treatment, with both the placebo and
the moxifloxacin-treated groups showing equal increases
in eosinophilic neurons and tissue damage. In addition, no
particular effect of moxifloxacin treatment on the functionalrdiovascular Surgery c Volume 141, Number 3 799
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FIGURE 3. Histologic outcomes 1 and 14 days after deep hypothermic cir-
culatory arrest (DHCA). A, At 1 day after deep hypothermic circulatory ar-
rest, both deep hypothermic circulatory arrest groups show increased
numbers of eosinophilic neurons in hippocampus. Data are presented as
box and whisker plot. Section mark indicates P<.001 versus sham.Dashed
line marks 90th percentile of untreated control animals. B, At 14 days after
deep hypothermic circulatory arrest, both deep hypothermic circulatory ar-
rest groups show worse histologic outcomes. Data are presented as box and
whisker plot. Section mark indicates P ¼ .006 versus sham. Dashed line
marks 90th percentile of untreated control animals.
§
FIGURE 4. Motor function 1 day after deep hypothermic circulatory arrest
(DHCA) was equally impaired in both deep hypothermic circulatory arrest
groups relative to preoperative baseline and to sham groups. Preoperative
baseline is not depicted (0 in all 4 groups). Data are presented as box and
whisker plot. Section mark indicates P< .001 versus sham.
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period, moxifloxacin treatment did not improve motor func-
tion 24 hours after DHCA. The long-term neurocognitive
performance remained equally unaffected by moxifloxacin,
despite a marked downregulation of inflammatory parame-800 The Journal of Thoracic and Cardiovascular Surgters in the early postoperative phase in the hippocampus,
a formation known to be crucial for learning and memory
function.15
Considering our results, one wonders why moxifloxacin
treated-mice have shown a better outcome after stroke.1
The answer is likely to be found within the essential differ-
ence between stroke and CPB with DHCA. Stroke is fol-
lowed by secondary infection, such as pneumonia, which
accounts for most associated morbidity and mortality.2
CPB with DHCA in our model, in contrast, triggers an in-
flammatory response without infection.6,7 In consequence,
one would expect the antibiotic moxifloxacin to improve
outcome after infection in the setting of a stroke model.1
Moxifloxacin reduced cerebral levels of TNFa, NFkB,
and COX-2 24 hours after CPB with DHCA in this study
but had no impact on histologic and functional outcomes.
This finding adds to the current debate about significance
of brain inflammation after bypass surgery in terms of
cognitive outcome, recently questioned in an editorial by
Nussmeier and Searles.16 Reviewing and discussing the
most recent findings, Nussmeier and Searles16 concluded
that the inflammatory response to CPB is likely not the
primary driver of neurocognitive injury after CPB. This
notion has been confirmed by the results of this study.
Finally, some important limitations remain. This study
was performed in young, healthy animals without any co-
morbidities identified as risk factors for adverse cerebral out-
come, such as diabetes, congenital heart disease, orery c March 2011
§§
FIGURE 5. Motor function, cognitive performance, and behavior 14 days
after deep hypothermic circulatory arrest (DHCA). A, Long-term motor
function was similarly affected in both deep hypothermic circulatory arrest
groups Section mark indicates P ¼ .018 versus sham. B, Both deep hypo-
thermic circulatory arrest groups showed equally impaired cognitive perfor-
mance 14 days after deep hypothermic circulatory arrest. Section mark
indicates P ¼ .021 versus sham. C, Behavior showed no difference among
all 4 groups. Data are presented as box and whisker plots. Score (value 0) for
untreated control is not depicted.
Kellermann et al Evolving Technology/Basic Science
The Journal of Thoracic and Casignificant atheromatous disease of the aorta, such as may be
found in the aging patient population presenting for cardiac
surgery.17 In addition, because only a single dose of moxi-
floxacin with a particular treatment regimen (6 3 400 mg/
kg distributed through 10 hours) was investigated, we can-
not rule out the possibility that a different dosage or treat-
ment scheme might have an impact on functional outcome
in this particular setting.CONCLUSIONS
Moxifloxacin penetrates the blood–brain barrier during
CPB with DHCA in rats. In the brain, it transiently amelio-
rates the cerebral inflammatory reaction in the absence of
postoperative infection. The fact that this significantly re-
duced cerebral inflammation had no impact on histologic
or biochemical outcome adds another piece of evidence to-
ward the theory that inflammation after CPB is likely an epi-
phenomenon and not the main culprit in postoperative
neurocognitive dysfunction.
We thank Simone Denzler for neurologic and neurocognitive
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